Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052267 · ClinicalTrials.gov registry record · Phase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
A Phase 3 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,700
- Enrollment target
- 20
- Study locations
NCT06052267: Recruiting Phase 3 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT06052267 is a Phase 3 study of Asthma that is actively recruiting participants, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 2,700 participants, above the 1,556-participant average among 374 other Asthma trials with a reported enrollment target (74% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06052267, a Phase 3 study of Asthma, is actively recruiting participants, sponsored by Teva Branded Pharmaceutical Products R&D.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS low dose compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each participant will be a minimum of 28 weeks including 2 weeks of screening, 2-4 weeks of run-in period and a double blind treatment period of minimum 24 weeks, however due to the event-driven nature of this study, the duration may range up to approximately 42 months depending on the timing when the participant was enrolled to the study, and when the study reaches its completion criteria
Conditions Studied
Interventions
- DRUG TEV-56248
- DRUG Albuterol sulfate
Study Locations (20)
California
- Teva Investigational Site 15685 - Bakersfield
- Teva Investigational Site 15721 - Fresno
- Teva Investigational Site 15788 - Huntington Beach
- Teva Investigational Site 15720 - La Jolla
- Teva Investigational Site 15687 - La Palma
- Teva Investigational Site 15708 - Long Beach
- Teva Investigational Site 15712 - Long Beach
- Teva Investigational Site 15643 - Los Angeles
- Teva Investigational Site 15695 - Napa
- Teva Investigational Site 15692 - Northridge
- Teva Investigational Site 15682 - Redondo Beach
- Teva Investigational Site 15629 - San Bernardino
- Teva Investigational Site 15709 - San Diego
- Teva Investigational Site 15704 - San Jose
Alabama
- Teva Investigational Site 15706 - Birmingham
- Teva Investigational Site 15786 - Birmingham
- Teva Investigational Site 15768 - Dothan
Arizona
- Teva Investigational Site 15581 - Paradise Valley
- Teva Investigational Site 15710 - Scottsdale
- Teva Investigational Site 15661 - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,700 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 3 |
What NCT06052267 shows while recruiting
NCT06052267 is an interventional study that assigns participants to a tested intervention. Its 2,700 participants enrollment target places it among the larger protocols in the corpus, above the 1,556-participant average among 374 other Asthma trials with a reported enrollment target (74% higher).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which TEV-56248 is the first listed.
NCT06052267 names 20 study sites across 3 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06052267 about?
NCT06052267 is a clinical study titled "A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations". The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To e...
What is the current status of trial NCT06052267?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,700 participants. The study started on 2023-08-30. Estimated completion is 2026-10-31.
What conditions does trial NCT06052267 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06052267?
The interventions under investigation include: TEV-56248 (DRUG), Albuterol sulfate (DRUG).
Who is sponsoring clinical trial NCT06052267?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06052267 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06052267's enrollment target sits among peer trials
2,700 20th of 374 higher than 355 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
- NCT07029490 · 2,700 participants · NA
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI